New approach in management of vitreo-retinal interface disorders with ocriplasmine
Article Sidebar
Published:
Mar 31, 2014
Keywords:
vitrea-retinal interence disorders, ocriplasmine, macular hole, vitreomacular traction syndrome
Main Article Content
Abstract
Symptomatic diseases of vitreo-retinal interface can result in traction and macular hole. Standard treatment for these disorders is pars plana vitrectomy. Ocriplasmine is a proteolytic enzyme that can cause resolution of the symptoms and replace surgical procedure in selected cases.
Downloads
Download data is not yet available.
Article Details
How to Cite
1.
Oficjalska J. New approach in management of vitreo-retinal interface disorders with ocriplasmine. Ophthatherapy [Internet]. 2014Mar.31 [cited 2024Jul.3];1(1):21-5. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/667
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Barak Y, Ihnen MA, Schaal S. Spectral domain optical coherence tomography in the diagnosis and management of vitreoretinal interface pathologies. Journal of Ophthalmology. 2012; Article ID 876472. http://dx.doi.org/10.1155/2012/876472.
2. Gandorfer A. Objective of pharmacologic vitreolysis. Dev Ophthalmol. 2009; 44: 1-6.
3. Aerts F, Noppen B, Fonteyn . et al. Mechanism of inactivation of ocriplasmin in porcine vitreous. Biophys Chem. 2012; 165-166: 30-8.
4. Duker JS, Kaiser PK, Binder S et al. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology. 2013; 120(12): 2611-9.
5. Stalmans P, Benz MS, Gandorfer A et al; MIVI-TRUST Study Group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012; 367(7): 606-15.
6. Geck U, Pustolla N, Baraki H et al. Posterior vitreous detachment following intravitreal drug injection. Graefes Arch Clin Exp Ophthalmol. 2013; 251(7): 1691-5.
7. Wong SC, Capone A Jr. Microplasmin (ocriplasmin) in pediatric vitreoretinal surgery: update and review. Retina. 2013; 33(2): 339-48.
2. Gandorfer A. Objective of pharmacologic vitreolysis. Dev Ophthalmol. 2009; 44: 1-6.
3. Aerts F, Noppen B, Fonteyn . et al. Mechanism of inactivation of ocriplasmin in porcine vitreous. Biophys Chem. 2012; 165-166: 30-8.
4. Duker JS, Kaiser PK, Binder S et al. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology. 2013; 120(12): 2611-9.
5. Stalmans P, Benz MS, Gandorfer A et al; MIVI-TRUST Study Group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012; 367(7): 606-15.
6. Geck U, Pustolla N, Baraki H et al. Posterior vitreous detachment following intravitreal drug injection. Graefes Arch Clin Exp Ophthalmol. 2013; 251(7): 1691-5.
7. Wong SC, Capone A Jr. Microplasmin (ocriplasmin) in pediatric vitreoretinal surgery: update and review. Retina. 2013; 33(2): 339-48.